Amarantus management has outlined two distinct pat

Quote:

---

Amarantus management has outlined two distinct paths for Elto Pharma to extract as much value for the Eltoprazine asset for Amarantus as possible: 1) standalone private funding followed by a US or Hong Kong-based IPO, or 2) a business combination with an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline in which Amarantus could become a significant shareholder. Amarantus expects to make a final determination on the capital formation plan for Elto Pharma in the summer of 2018.

---

This deal obviously fell through. Because Coeptis is clearly not "an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline."

Not by any stretch.